ArticleIn vivo (Athens, Greece)
Comparison of the Use of Immune Checkpoint Inhibitor/Tyrosine Kinase Inhibitor and Tyrosine Kinase Inhibitor Alone for Patients With Low Risk Metastatic Renal Cell Carcinoma.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative Analysis of Immune-based Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma.In vivo (Athens, Greece)Article
- Onset and Outcomes of Immune-related Adverse Events in Genitourinary Cancer Treated With Immune Checkpoint Inhibitors.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimCurrently, a combination of an immune checkpoint inhibitor (ICI) and a tyrosine kinase inhibitor (TKI) is the most widely used first-line treatment for metastatic renal cell carcinoma (mRCC). However, patients in the IMDC favourable risk group have been reported to have a relatively good prognosis, even when they undergo TKI monotherapy. The aim of this study was to evaluate whether ICI/TKI combination therapy or TKI monotherapy is more effective in patients with favourable IMDC risk. PATIENTS AND
methodsWe retrospectively reviewed 11 patients with favourable IMDC risk who underwent ICI/TKI combination therapy and 12 who underwent TKI monotherapy as first-line treatment for mRCC at our institution between April 2008 and September 2024 and compared their characteristics and treatment outcomes. The endpoints were overall survival (OS), progression-free survival (PFS) and treatment response, which was assessed using the overall response rate (ORR) and disease control rate (DCR). The safety of the regimens was evaluated using the incidences of grade ≥3 adverse events (AEs) and treatment discontinuation.
resultsThere was a significant difference between the groups regarding the duration of follow-up (24.4 months for the ICI/TKI group
conclusionBased on its superiority with respect to ORR and AE at our Institution, ICI/TKI therapy should be considered whenever possible, even in patients in the IMDC favourable risk group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.